ReviewDiagnostics (Basel, Switzerland)2024
Hyperglycemia and Venous Thromboembolism.
Review in Diagnostics (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Venous thromboembolism with modern glucose-lowering agents in diabetes: active-comparator evidence beyond placebo-based meta-analyses.Internal and emergency medicine · 2026Pooled it
- Malignancy as a Predictor and Potential Modifier of Laboratory Biomarker Prognostic Value in Acute Pulmonary Embolism.Diagnostics (Basel, Switzerland) · 2026Article
- Perioperative outcomes of total and unicompartmental knee arthroplasty in patients with Type 2 diabetes mellitus: A propensity score-matched analysis.Journal of experimental orthopaedics · 2026Article
- Association between intrinsic capacity, genetic predisposition, and risk of venous thromboembolism.Journal of vascular surgery. Venous and lymphatic disorders · 2026Article
- Prior intra-articular sodium hyaluronate injection as a novel predictor of isolated distal deep vein thrombosis after knee surgery: development and validation of a 5-factor nomogram.Research and practice in thrombosis and haemostasis · 2026Article
- Cardiometabolic multimorbidity and short-term outcomes in pulmonary embolism: Findings from the CURES Registry-2.American journal of preventive cardiology · 2026Article
- Risk factors and a predictive nomogram for in-hospital deep vein thrombosis in elderly patients with multiple chronic conditions.American journal of translational research · 2026Article
- A case description of multisystem tuberculosis complicated with diabetes mellitus and pulmonary embolism.Quantitative imaging in medicine and surgery · 2026Article
- Risk prediction model for thrombosis in leukemia patients: a systematic review.Frontiers in oncology · 2026Review
- Causal associations between diet and thromboembolism: A 2-sample Mendelian randomization study.Medicine · 2025Article
- Risk factors for venous thromboembolism after knee arthroscopy: a systematic review and meta-analysis.Thrombosis journal · 2025Review
- Review
- Developing a predictive model for lower extremity deep vein thrombosis in acute ischemic stroke using a nomogram.Frontiers in neurology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with diabetes mellitus (DM) have chronically increased blood glucose and multiple physiologic alterations that place them at elevated risk for vascular disease. Traditionally, this vascular risk has mainly referred to chronic atherosclerosis and embolic arterial disease. Retrospective studies have suggested an increased risk of a pulmonary embolism (PE) and deep vein thrombosis (DVT), collectively termed venous thromboembolism (VTE), in patients with DM, but this association has been difficult to demonstrate with comorbidities such as obesity in meta-analysis. Clinical studies have demonstrated worse outcomes for patients with DM who suffer from VTE. In vitro studies show multiple physiologic abnormalities with chronic inflammation, endothelial dysfunction, dysfunction in the coagulation cascade, as well as other changes that drive a vicious cycle of hypercoagulability. Aggressive medical management of DM can improve vascular outcomes, and some anti-hyperglycemic therapies may modify VTE risk as well. Anticoagulation strategies are similar for patients with DM, but with some added considerations, such as high rates of comorbid renal dysfunction. More research is needed to definitively categorize DM as a risk factor for VTE and elucidate specific therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.